Airing in journal a further step forward for ENA Respiratory

ENA Respiratory, an Australian pharma developing innate immune modulators to prevent complications associated with respiratory viral infections in at-risk populations, has announced the publication of results of its Phase IIa study with its liquid formulation of INNA-051 in ERJ Open Research.

The publication, in what is a research journal of the European Respiratory Society, also includes data from ENA Respiratory’s dose-escalation study to assess tolerability and mechanistic biomarkers following single and repeated intranasal administrations of INNA-051 in individuals aged 18 to 55 years.

Headline results of the challenge study, conducted in the UK in 123 healthy volunteers, were first announced in February 2023, with further analyses announced in September 2023.